Accelerator Corp raises $51.1 mln for fourth fund

Accelerator Corp. said Tuesday that it has raised $51.1 million in the first close of its fourth fund. The pool’s investors include Alexandria Venture Investments, ARCH Venture Partners, WRF Capital, Eli Lilly, Harris & Harris Group, Johnson & Johnson Development Corp., The Partnership Fund for New York City and Pfizer Venture Investments. Based in Seattle and New York City, Accelerator Corp is a biotech investment firm.


Rodin Therapeutics snags $12.9 mln Series A

Rodin Therapeutics has secured $12.9 million in Series A financing. Previous backers Atlas Venture and Johnson & Johnson Development Corp. led the round. Also, the company has named Barbara Tate as head of biology. Based in Cambridge, Mass., Rodin is a biotech firm focused on treating neurological disorders.

OrbiMed leads $40 mln round for Inspire Medical Systems

Inspire Medical Systems said Thursday that it has closed $40 million in Series E financing. OrbiMed led the round with participation from Johnson & Johnson Development Corp, Aperture Venture Partners, Kleiner Perkins Caufield & Byers, US Venture Partners, Synergy Life Science Partners, Medtronic, GDN Holdings and TGap Ventures. In addition to the funding, OrbiMed’s Chau Q. Khuong has been added to Inspire Medical Systems’ board of directors. Based in Minneapolis, Inspire Medical Systems is a maker of of an implanted device that treats a subset of patients with obstructive sleep apnea.

Atlas Genetics nabs Series B funds

Atlas Genetics has raised 16.9 million pounds in Series B funding. The investors in this round include Novartis Venture Funds, Consort Medical plc, Life Sciences Partners, BB Biotech Ventures, Johnson & Johnson Development Corp. and YFM Equity Partners. Based in Bath, England, Atlas is a diagnostics company that provides tests for infectious diseases.

Slideshow: Where the Biotech & Device Investors Are–Q4 Edition

Lately, there’s been a whole lot of bemoaning of this and that to explain why VCs are abandoning the biotech and device space and why strategics are slowing early-stage funding. Lawmakers and regulators have made it too tough to IPO. Lawmakers and regulators have made it too tough to get anything approved at the FDA. […]

Biocartis Adds $100M Equity Financing

Swiss biotech start-up Biocartis has raised 71 million euro ($100 million) in Series C financing. Investors in the round include Debiopharm Group, Philips, Johnson & Johnson Development Corp., the Wellcome Trust, Korys, Valiance and Biovest. The money will be used to help commercialize the company’s compact molecular diagnostics system.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget